Utilizing nanocurcumin to increase the efficacy of diabetes type I cell therapy

The prevalence of diabetes for all age-groups worldwide was estimated to be 2.8% in 2000 and 4.4% in 2030 based onWHO reports. The main reason for diabetes type I is that pancreatic beta cells do not produce insulin sufficiently.Organ/islet transplantation and daily insulin injection are conventional therapeutic/treatment methods which have beenutilized until now. The search for alternatives has started several years ago and methods based on stem cells (SCs)differentiation are an ongoing task. Type I diabetes therapy should potentially benefit from such differentiated cells. Animportant obstacle on the way of this kind of cell-based therapy is the risk of tumorigenecity in the patients benefitfrom these transplanted cells due to undifferentiated cells which participate in transplantation. Curcumin, the maincompound of spice turmeric- as one of the natural products- is demonstrated to possess effective anti-cancer properties,with no significant effect on normal cells. Therefore we based the main aim of this study on improving the efficiency ofdifferentiating human mesenchymal stem cells (hMSCs) into IPCs and eradicating undifferentiated cells bynanocurcumin. Curcumin bioavailability could be improved using nanoparticle carriers (nanocurcumin).We treatedcells with the appropriate dose of nanocurcumin after differentiation. Real time PCR for insulin gene performed. Ourdata indicates that polymeric nanocurcumin -in specific dose – eradicated undifferentiated cells with no significanteffect on insulin expression level.

کلیدواژه ها:

polymeric nanocurcumin ، diabetes type I ، regenerative medicine ، MSCs ، IPCs ، tumorigenesity